CryoPort (NASDAQ:CYRX) Share Price Crosses Above Two Hundred Day Moving Average – Here’s Why

Shares of CryoPort, Inc. (NASDAQ:CYRX) crossed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $10.60 and traded as high as $15.04. CryoPort shares last traded at $14.76, with a volume of 443,402 shares traded.

Analyst Ratings Changes

A number of research analysts have commented on the company. KeyCorp increased their target price on CryoPort from $15.00 to $17.00 and gave the stock an “overweight” rating in a report on Wednesday, May 20th. Wall Street Zen raised CryoPort from a “sell” rating to a “hold” rating in a research report on Monday, May 11th. Weiss Ratings raised CryoPort from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Wednesday, May 6th. Guggenheim raised their price objective on CryoPort from $11.00 to $12.00 and gave the stock a “buy” rating in a research note on Tuesday, May 5th. Finally, Craig Hallum lifted their price objective on shares of CryoPort from $15.00 to $20.00 and gave the stock a “buy” rating in a report on Wednesday, June 3rd. Eight analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat.com, CryoPort currently has a consensus rating of “Moderate Buy” and a consensus target price of $15.11.

CryoPort Stock Performance

The firm has a market cap of $800.35 million, a P/E ratio of 11.76 and a beta of 1.90. The firm has a fifty day moving average of $13.32 and a 200-day moving average of $10.64.

CryoPort (NASDAQ:CYRX) last issued its quarterly earnings data on Monday, May 4th. The company reported ($0.23) EPS for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.03). CryoPort had a negative return on equity of 7.92% and a net margin of 41.57%.The company had revenue of $47.80 million for the quarter, compared to the consensus estimate of $44.86 million. Equities research analysts expect that CryoPort, Inc. will post -0.85 earnings per share for the current year.

Insider Activity

In related news, insider Edward J. Zecchini sold 33,600 shares of CryoPort stock in a transaction dated Thursday, June 11th. The shares were sold at an average price of $14.47, for a total value of $486,192.00. Following the sale, the insider directly owned 109,719 shares in the company, valued at $1,587,633.93. This trade represents a 23.44% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Robert Stefanovich sold 169,427 shares of the business’s stock in a transaction dated Thursday, June 4th. The shares were sold at an average price of $16.27, for a total transaction of $2,756,577.29. Following the transaction, the chief financial officer directly owned 109,850 shares of the company’s stock, valued at $1,787,259.50. The trade was a 60.67% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 227,641 shares of company stock valued at $3,622,515. 10.00% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On CryoPort

Several large investors have recently made changes to their positions in the company. UBS Group AG increased its position in CryoPort by 6.8% in the 4th quarter. UBS Group AG now owns 1,421,884 shares of the company’s stock valued at $13,650,000 after acquiring an additional 90,363 shares during the period. Mak Capital One LLC bought a new stake in CryoPort during the 3rd quarter valued at $7,756,000. First Eagle Investment Management LLC acquired a new position in CryoPort during the 4th quarter worth $2,996,000. Meros Investment Management LP boosted its position in CryoPort by 13.9% during the 4th quarter. Meros Investment Management LP now owns 626,427 shares of the company’s stock worth $6,014,000 after acquiring an additional 76,687 shares during the period. Finally, Legato Capital Management LLC bought a new position in shares of CryoPort in the fourth quarter worth $443,000. Institutional investors and hedge funds own 92.90% of the company’s stock.

CryoPort Company Profile

CryoPort, Inc (NASDAQ: CYRX) is a global provider of temperature-controlled logistics solutions for the life sciences industry. The company specializes in cryogenic shipping for critical biological materials, supporting the development, clinical testing and commercialization of cell and gene therapies, biologics, vaccines and reproductive medicine. By offering end-to-end supply chain management, CryoPort helps ensure the integrity and viability of temperature-sensitive products from point of origin to destination.

CryoPort’s product portfolio includes proprietary cryogenic dry shippers, advanced active and passive thermal packaging, and real-time data monitoring platforms.